✦ LIBER ✦

Combined Modality Treatment for PET-Positive Non-Hodgkin Lymphoma: Favorable Outcomes of Combined Modality Treatment for Patients With Non-Hodgkin Lymphoma and Positive Interim or Postchemotherapy FDG-PET

✍ Scribed by Lia M. Halasz; Heather A. Jacene; Paul J. Catalano; Annick D. Van den Abbeele; Ann LaCasce; Peter M. Mauch; Andrea K. Ng

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined modality treatment is the treat

✍ R.W.M van der Maazen; E.M Noordijk; J Thomas; J.M.M Raemaekers; J.H Meerwaldt 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 120 KB

1007 Accuracy of end of treatment 18F-FD

✍ G. Jerusalem; V. Warland; Y. Beguin; R. Hustinx; M.F. Fassotte; J. Foidart-Wille 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 165 KB

The combined evaluation of interim contr

✍ Deok-Hwan Yang; Jung-Joon Min; Yong Yeon Jeong; Jae-Sook Ahn; Yeo-Kyeoung Kim; S 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 196 KB

Combination of ibrutinib with rituximab,

✍ Younes, Anas; Thieblemont, Catherine; Morschhauser, Franck; Flinn, Ian; Friedber 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 305 KB